Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CA3 | P07451 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13469248 | 0.89 | HPGD (0.57) | HPGDKDM4EALDH1A1CA12CA2 | |
| SCHEMBL3481117 | 0.88 | HPGD (0.53) | HPGDKDM4EALDH1A1CA12CA2 | |
| SCHEMBL149036 | 0.86 | KDM4E (0.55) | HPGDKDM4EALDH1A1CA12CA2 | |
| SCHEMBL15478784 | 0.85 | HPGD (0.53) | HPGDKDM4EALDH1A1CA12CA2 | |
| SCHEMBL3481112 | 0.84 | CYP4F2 (0.45) | HPGDKDM4EALDH1A1CA12CA2 | |
| SCHEMBL26612154 | 0.84 | POLB (0.46) | HPGDKDM4EALDH1A1CA12CA2 | |
| SCHEMBL25386200 | 0.84 | ALDH1A1 (0.52) | HPGDKDM4EALDH1A1CA12CA2 | |
| SCHEMBL27089477 | 0.83 | HPGD (0.49) | HPGDKDM4EALDH1A1CA12CA2 | |
| SCHEMBL3481164 | 0.83 | CYP4F2 (0.44) | HPGDKDM4EALDH1A1CA12CA2 | |
| SCHEMBL4832019 | 0.83 | CYP4F2 (0.51) | HPGDKDM4EALDH1A1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215074-B1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | US HEALTH (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2215074-B1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | US HEALTH (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2573080-A1 | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses | The United States of America, as Represented by the Secretary, Department of Health and Human Services (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2573080-A1 | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses | The United States of America, as Represented by the Secretary, Department of Health and Human Services (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
| EP-2215074-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as Represented by the Secretary, Department of Health and Human Services (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009042907-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042907-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-1993014086-A1 | SUBSTITUTED 1-ISOQUINOLONE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, SYNCRIP, RNMT | HPGD 1721/4885KDM4E 3219/4885ALDH1A1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.